Fresenius Medical Care stock: analysis & valuation

FME.DEMedical Care FacilitiesGermanyData as of Nov 15, 2026
Metrics analysis · Medical Care Facilities

Fresenius Medical Care FME.DE

Price 40.11 EUR +1.39%Market cap 10.4 bn EUR52 weeks 34.57 – 45.90
Forward P/E
10.5x
Industry 16.2x
EV/EBITDA
7.9x
Industry 12.3x
Revenue growth
1.1%
Industry 6.5%
Operating margin
10.1%
Industry 10.1%
Return on equity
7.8%
Industry 15.4%
Free cash flow yield
14.3%
Industry 3.8%

What does Fresenius Medical Care do?

Fresenius Medical Care is a globally active provider of dialysis services and related products for people with chronic kidney disease. The core of the business is the operation of a large network of outpatient dialysis clinics where patients are treated regularly. In addition, the company offers laboratory services, diagnostics, patient care and dialysis services on behalf of hospitals, particularly in the US.

The company is divided into the Care Delivery and Care Enablement segments. Care Delivery covers patient treatment, while Care Enablement covers the development, manufacture and distribution of dialysis machines, dialyzers, consumables and other healthcare products. Its customers are patients, payers such as government and private insurers, as well as hospitals and other dialysis providers. Through the combination of treatment and in-house manufacturing, the company is among the world's leading providers in the dialysis market, which is shaped by a few large competitors.

Score profile

Quality3.7
Valuation8.0
Growth1.0
Financial strength4.8
Momentum5.2

Rank vs. Medical Care Facilities (21 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.

Metrics compared with the industry

On profitability and quality, Fresenius Medical Care ranks below average in the group Medical Care Facilities (3.7/10). On growth, the company ranks in the bottom fifth in the group Medical Care Facilities (1.0/10). On valuation (higher = cheaper), the stock ranks among the best in the group Medical Care Facilities (8.0/10). On financial strength, Fresenius Medical Care ranks in the middle in the group Medical Care Facilities (4.8/10).

MetricStockGroup medianRanking
Forward P/E10.5x16.2xbetter than 82 %
Trailing P/E13.5x19.7xbetter than 81 %
PEG ratio1.0x1.4xbetter than 68 %
EV/EBITDA7.9x12.3xbetter than 83 %
Price/sales0.5x1.3xbetter than 88 %
Price/book0.8x3.2xbetter than 97 %
Revenue growth1.1%6.5%better than 7 %
Earnings growth-35.4%6.5%better than 13 %
Gross margin26.5%29.9%better than 40 %
Operating margin10.1%10.1%better than 50 %
Net margin4.2%6.6%better than 31 %
Return on equity7.8%15.4%better than 26 %
Debt/equity79.3%78.7%better than 45 %
Current ratio1.0x1.4xbetter than 7 %
Free cash flow yield14.3%3.8%better than 93 %
Dividend yield3.7%0.6%–
Payout ratio50.0%12.5%–
Beta0.790.77–

Valuation: what is Fresenius Medical Care worth?

Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Fresenius Medical Care a model range of 62.08 EUR to 93.91 EUR per share.

Price 40.11 EUR
Analysts 39.68 EUR
Fair value range 62.08 EUR – 93.91 EURMidpoint 86.18 EUR (+114.9% vs. price)

17 analysts, average rating “Hold”, average price target 39.68 EUR (−1.1%).

The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.

What the business depends on

  • The number of dialysis patients grows structurally with population aging and the spread of diabetes and high blood pressure.
  • Reimbursement rates and the payer mix of government and private payers largely determine the earnings power of treatments.
  • Vertical integration of clinic operations and in-house production of machines and consumables creates economies of scale and stable demand.

Risks

  • Changes to reimbursement systems and healthcare policy, especially in the US, can significantly weigh on treatment margins.
  • Staff shortages and rising wage costs in the clinics increase cost pressure, as the business is highly labor-intensive.
  • New therapies for kidney disease or diabetes could, over the long term, affect the number of dialysis patients and demand for treatment.

What to look for with Fresenius Medical Care

The operating margin in the Care Delivery segment is particularly informative because it shows how well reimbursement, treatment volume and personnel costs work together.

Full AI analysis of Fresenius Medical Care

The AI evaluates all the numbers above and turns them into an assessment with a score, strengths and weaknesses, a fair value range and risks – from €1.99; Plus (€4.99) adds business model, moat and scenarios, Pro (€9.99) also peer comparison and reverse DCF. See an example.

Analyze a stock

Results in minutes
1 Choose a stock
2 Choose the depth

See what you get first: Example Compact (Apple) PDF Plus example (Microsoft) PDF Example Pro (NVIDIA) PDF

3 Delivery
Secure payment via Stripe Report by email + PDF No subscription

Frequently asked questions about Fresenius Medical Care stock

What is the P/E ratio of Fresenius Medical Care stock?

Based on expected earnings, Fresenius Medical Care trades at a P/E of 10.5x, compared with a median of 16.2x for the peer group Medical Care Facilities. Based on the earnings of the last twelve months it is 13.5x. (data as of Nov 15, 2026)

Does Fresenius Medical Care pay a dividend?

Yes. The dividend yield is currently 3.7%, with a payout ratio of 50.0% of earnings.

Is Fresenius Medical Care stock undervalued?

Measured by valuation metrics (P/E, EV/EBITDA, price/sales, PEG), Fresenius Medical Care is currently valued cheaper than most companies in the group Medical Care Facilities (valuation score 8.0 out of 10). Our model calculations (DCF and industry multiples) give a range of 62.08 EUR to 93.91 EUR per share at a price of 40.11 EUR. This is a model calculation, not an investment recommendation.

What do analysts say about Fresenius Medical Care stock?

17 analysts have an average price target of 39.68 EUR (−1.1% vs. the current price); the average rating is “Hold”. Analyst targets are opinions and change frequently.

Comparable stocks

All information without guarantee. Metrics from public market data, updated daily; company profile written editorially with the help of AI. Not investment advice and not a solicitation to buy or sell securities.